DS
CYT

David Shaw’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

David Shaw’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-58,529
Closed -$175K – 5637
2022
Q2 		$175K Sell
58,529
-13,330
-19% -$34K ﹤0.01% 4592
2022
Q1 		$271K Buy
71,859
+48,146
+203% +$274K ﹤0.01% 4709
2021
Q4 		$270K Buy
+23,713
New +$361K ﹤0.01% 4729

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Shaw's CYT Position: Q3 2022 in Review

David Shaw sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2022, closing a stake of 58,529 shares — an estimated $175K sold.

David Shaw first reported a position in CYT in Q4 2021 and held it in 3 quarters. The position peaked at $271K in Q1 2022. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • David Shaw reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 58,529 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $175K.
  • David Shaw first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • David Shaw's Cyteir Therapeutics, Inc. Common Stock position peaked at $271K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.